Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5379321 | 0.82 | KCNA5 (0.51) | CHRNB2CHRNA4HTTCHRNA7KCNA5 | |
| SCHEMBL2104038 | 0.82 | CHRNB2 (0.46) | CHRNB2CHRNA4HTTCYP2A6CHRNA7 | |
| SCHEMBL10771297 | 0.81 | TRPV1 (0.48) | CHRNB2CHRNA4HTTCHRNA7KCNA5 | |
| SCHEMBL1432726 | 0.81 | NPSR1 (0.51) | CHRNB2CHRNA4HTTCYP2A6KCNA5 | |
| SCHEMBL26846250 | 0.81 | CHRNB2 (0.50) | CHRNB2CHRNA4HTTCYP2A6CHRNA7 | |
| SCHEMBL13068652 | 0.80 | CHRNA7 (0.55) | CHRNB2CHRNA4CYP2A6CHRNA7KCNA5 | |
| SCHEMBL20729482 | 0.80 | CYP2A6 (0.52) | CHRNB2CHRNA4CYP2A6CYP2C19 | |
| SCHEMBL6834283 | 0.79 | POLB (0.51) | CHRNB2CHRNA4HTTCHRNA7KCNA5 | |
| SCHEMBL6847317 | 0.79 | CHRNA7 (0.44) | CHRNB2CHRNA4CYP2A6CHRNA7KCNA5 | |
| SCHEMBL29435745 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117720533-A | MetTL3 inhibitor compound and pharmaceutical composition and application thereof | 北京华益健康药物研究中心 | 2024-03-19 | — | — | CN | disclosed |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11612657-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| CN-114957347-A | Preparation method of bipyridyl copper-zinc heterobinuclear macrocyclic complex | 武汉轻工大学 | 2022-08-30 | — | — | CN | disclosed |
| US-11382979-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220175930-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2022-06-09 | — | — | US | disclosed |
| US-20220175929-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2022-06-09 | — | — | US | disclosed |
| US-20220125927-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2022-04-28 | — | — | US | disclosed |
| US-11246933-B1 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-6673790-B1 | ANTAGONIST OF OXYTOCIN RECEPTORS USED IN COMBINATION WITH ANTAGONIST OF VASOPRESSIN V1A RECEPTORS FOR TREATMENT OF DYSMENORRHEA OR ENDOMETRIOSIS OR CONTROL OF PREMATURE LABOR AND FOR CONTROLLING PREPARATORY LABOR FOR CAESAREAN DELIVERY | SANOFI-SYNTHELABO (FR) | 2004-01-06 | — | — | US | disclosed |
| CN-1427825-A | Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands | SANOFI SYNTHELABO (FR) | 2003-07-02 | — | — | CN | disclosed |
| CN-1083432-C | Alpha-unsaturated amines, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-04-24 | — | — | CN | disclosed |
| CN-1036649-C | Alpha-unsaturated amines, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-12-10 | — | — | CN | disclosed |
| EP-0734378-A1 | AMINOSULPHONYL-PHENYL-1H-PYRROLE DERIVATIVES, METHOD OF THEIR PREPARATION AND THEIR USE | SMITHKLINE BEECHAM PLC (GB) | 1996-10-02 | — | — | EP | disclosed |
| CN-1120436-A | A remedy for bronchial asthma | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1996-04-17 | — | — | CN | disclosed |
| WO-1995016674-A1 | AMINOSULPHONYL-PHENYL-1H-PYRROLE DERIVATIVES, METHOD OF THEIR PREPARATION AND THEIR USE | SMITHKLINE BEECHAM PLC (GB) | 1995-06-22 | — | — | WO | disclosed |
| CN-1027447-C | Insecticidal/acaricidal composition containing alpha-unsaturated amine | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-01-18 | — | — | CN | disclosed |
| CN-1093083-A | The method for preparing α-unsaturated amine or its salt | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-10-05 | — | — | CN | disclosed |
| CN-1031079-A | Alpha-unsaturated amines, process for their production and their use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1989-02-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175929-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | CHRNB2 4172/4885CHRNA4 4242/4885HTT 484/4885 |
| US-11612657-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | CHRNB2 4172/4885CHRNA4 4242/4885HTT 484/4885 |
| US-11382979-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | CHRNB2 4172/4885CHRNA4 4242/4885HTT 484/4885 |
| US-20220175930-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | CHRNB2 4172/4885CHRNA4 4242/4885HTT 484/4885 |
| US-11246933-B1 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | CHRNB2 4172/4885CHRNA4 4242/4885HTT 484/4885 |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | CHRNB2 4172/4885CHRNA4 4242/4885HTT 484/4885 |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | CHRNB2 4172/4885CHRNA4 4242/4885HTT 484/4885 |
| US-20220125927-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | CHRNB2 4172/4885CHRNA4 4242/4885HTT 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.